Janux Therapeutics (NASDAQ:JANX) Announces Earnings Results

Janux Therapeutics (NASDAQ:JANX) issued its earnings results on Thursday. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.10), FiscalAI reports. The business had revenue of $10.27 million during the quarter, compared to analyst estimates of $19.07 million.

Janux Therapeutics Stock Down 1.6%

Shares of NASDAQ JANX traded down $0.25 during trading on Friday, reaching $15.85. The company had a trading volume of 689,025 shares, compared to its average volume of 744,057. The stock has a market cap of $966.53 million, a P/E ratio of -9.66 and a beta of 2.50. The company’s fifty day moving average price is $15.04 and its 200-day moving average price is $14.44. Janux Therapeutics has a 12 month low of $12.12 and a 12 month high of $35.34.

Insider Buying and Selling

In other Janux Therapeutics news, insider Janeen Noel Doyle sold 4,059 shares of the stock in a transaction that occurred on Tuesday, June 2nd. The shares were sold at an average price of $14.03, for a total transaction of $56,947.77. Following the completion of the sale, the insider owned 75,941 shares of the company’s stock, valued at approximately $1,065,452.23. This represents a 5.07% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, VP Maria Dobek sold 2,038 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $14.17, for a total transaction of $28,878.46. Following the transaction, the vice president owned 32,270 shares of the company’s stock, valued at approximately $457,265.90. The trade was a 5.94% decrease in their position. The SEC filing for this sale provides additional information. 7.90% of the stock is owned by insiders.

Institutional Investors Weigh In On Janux Therapeutics

Several large investors have recently modified their holdings of the company. Osaic Holdings Inc. grew its stake in Janux Therapeutics by 704.6% during the second quarter. Osaic Holdings Inc. now owns 3,468 shares of the company’s stock worth $80,000 after purchasing an additional 3,037 shares during the period. Tower Research Capital LLC TRC boosted its holdings in shares of Janux Therapeutics by 175.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 3,928 shares of the company’s stock worth $91,000 after buying an additional 2,502 shares in the last quarter. Los Angeles Capital Management LLC acquired a new stake in shares of Janux Therapeutics during the 4th quarter worth approximately $137,000. Martingale Asset Management L P acquired a new stake in shares of Janux Therapeutics during the 4th quarter worth approximately $155,000. Finally, Federated Hermes Inc. bought a new stake in shares of Janux Therapeutics in the 4th quarter valued at $164,000. 75.39% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have recently commented on JANX shares. JonesTrading cut their price target on Janux Therapeutics from $50.00 to $28.00 and set a “buy” rating on the stock in a research note on Tuesday, April 28th. Evercore set a $22.00 price objective on shares of Janux Therapeutics in a report on Monday, May 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Janux Therapeutics in a research report on Monday, July 20th. Piper Sandler reduced their target price on shares of Janux Therapeutics from $30.00 to $26.00 and set an “overweight” rating on the stock in a report on Friday, May 8th. Finally, Truist Financial restated a “buy” rating and issued a $26.00 price target (down from $80.00) on shares of Janux Therapeutics in a research report on Thursday, June 25th. Nine investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, Janux Therapeutics has an average rating of “Moderate Buy” and an average price target of $37.58.

About Janux Therapeutics

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.